PreDiabetes
Conditions
Keywords
PreDiabetes, Metformin, Precision nutrition, SLC16A11, Mexican Mestizos
Brief summary
The goal of this randomized clinical trial is to determine the impact of the risk haplotype on SLC16A11 on early therapeutic responses in treatments to prevent T2D in Mexican mestizos with prediabetes. The main question\[s\] it aims to answer are: * Evaluate the effect of the risk haplotype on weigth loss \>3% * Evualuate the differences in lipid profiles and glycemic parameters (fasting glucose, HbA1c). Participants will be randomized into two groups: lifestyle intervention (LSI): hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week), or LSI + MET (750 mg metformin twice a day). Researchers will compare carriers and non carriers of the risk haplotype of SLC16A11 to see if there are diferent treatment responses.
Detailed description
Objectives: Dietary modification and/or metformin remain the most cost-effective treatment to prevent type 2 diabetes (T2D). Yet, there is an important variation in receiving the benefit among individuals. A haplotype in SLC16A11 is associated with decreased insulin action and risk for T2D in Mexicans. We aim to determine the impact of the risk haplotype on SLC16A11 on early therapeutic responses in treatments to prevent T2D. Methods: We recrute individuals with at least one prediabetes criteria according to the American Diabetes Association with a body mass index (BMI) between 25 and 45 kg/m2. Participants are randomized into two groups: lifestyle intervention (LSI): hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week), or LSI + MET (750 mg metformin twice a day). Standardized dietitians delivere the LSI. The treatment goal is to achieve \>3% weight loss during the 12-week follow-up. Participants are genotyped for the risk allele rs13342232 and rs75493593. The effects of the risk haplotype are evaluated with linear and logistic regressions adjusted by age, sex, five genetic principal components, BMI, and prediabetes criteria at baseline. Primary outcome is a significant interaction between the treatment arm and genotype in weight loss goal \>3% after the treatment. Secondary outcome are differences in lipid levels and third outcome is differences in glycemic parameters (fasting glucose, HbA1c).
Interventions
DRUGLife Style Intervention + Metformin
hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week) + Metformin extended release 750mg each 12 hours
BEHAVIORALLife Style Intervention
hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (\>150 min medium intensity per week)
Sponsors
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Mexican mestizos * At least one prediabetes criteria according to the American Diabetes Association: fasting glucose between 100-124 mg/dL, Glycosylated hemoglobin (HbA1c) between 5.7-6.4, and 2-hour blood sugar between 140 mg/dl-199 mg/dl after an oral load of 75g of glucose) (1); * Age ranged between 18-65 years * Overweight or obesity (BMI between 25.0 - 40 kg/m2).
Exclusion criteria
* Chronic diseases * Pregnancy * Chronic use of medications that altered plasma glucose levels.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in weigth loss | 12 weeks | Number of participants in each treatment arm reaching the the goal weight loss \>3% |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in LDL-Cholesterol parameters | 12 weeks | Decreasing LDL-Cholesterol levels (mg/dl) |
| Change in ApoB | 12 weeks | Decreasing ApoB levels (mg/dl) |
| Change in Total-Cholesterol parameters | 12 weeks | Decreasing concentration of Total-Cholesterol (mg/dl) |
| Change in fasting glucose | 12 weeks | Decreasing fasting glucose levels (mg/dl) |
| Change in HbA1c | 12 weeks | Decreasin HbA1c levels (%) |
| Change in NonHDL-Cholesterol | 12 weeks | Decreasin NonHDL-Cholesterol levels (mg/dl) |
Countries
Mexico
Outcome results
None listed